Canada markets closed

ProMIS Neurosciences, Inc. (PMN.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
7.50-0.20 (-2.60%)
At close: 03:49PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • A
    Arty
    Very pleasant surprise today
  • K
    Ken
    Much needed boost from NASDAQ listing potential. Let’s hope the potential gets before the wider audience…we shall see…
  • s
    sheep
    can't seem to get their act together. All we hear about is new 'hires'!
  • K
    Ken
    Great job Gene Williams and team! 
  • D
    Dann
    Is there a reason why my ARFXF shares have disappeared from my Ameritrade portfolio? Could it be related to the riverse split that was announced?
  • M
    Michael
    My understanding is that they did the 60-1 rs to raise sp to get on Nasdaq. But it wasn’t guaranteed. is there news they were accepted.
  • S
    Sue
    I have waited for this day for over 6 years! I’ve had patience for a PROMIS, and they finally delivered what they’ve hoped to accomplish for a long time. NASDAQ is going to be a game changer!
  • S
    Sean
    Only great news will save this if not say goodbye to half your money after the split.
  • l
    lil Mike
    trying to sell but can't, why?
  • D
    Del
    bought and held and now no buyers at all.
  • l
    lil Mike
    can some explain in detail what the heck is going on with this stock. please explain in a way a child could understand 🙏😅
  • l
    lawrence
    Down 15% today. Let's see how low it drifts
  • S
    Sean
    Big volume!
  • S
    Sean
    To bad it's not even 14cents after today
  • A
    Arty
    Lowest I have seen !!
  • T
    Terry
    Found this online: For ProMIS, Goldstein sees his company's PMN310 antibody becoming the next generation, best-in-class treatment for Alzheimer's. "We have preclinical evidence that PMN310 selectively targets and neutralizes the neurotoxicity without binding to normal, non-toxic forms of amyloid, such as plaque."
    PMN310 is in the late preclinical stage of development. Final steps to an IND file include completing the scale up manufacturing of PMN310, followed by start of the clinical trial program.
    To raise the funds to proceed, ProMIS is in discussion with "more than five and less than 10" pharmaceutical companies, some at the term sheet stage, Goldstein stressed. "Because we have distinct antibody programs running simultaneously for Alzheimer's, Parkinson's, ALS and frontotemporal dementia (FTD), there could potentially be more than one deal in the offing in the next three to twelve months."
    ProMIS has approximately 261 million shares outstanding, and around 25% are owned by insiders. The company plans to uplist to the NASDAQ when conditions become favorable.
    Noble Capital Markets opined on October 24, "We believe ProMIS's currently deflated share price does not reflect the potential of its lead drug PMN310 and unique mechanism of action targeting the true culprit of Alzheimer's disease, which makes it potentially superior to aducanumab. We are reiterating our Outperform rating and $1.00 target price on the stock." The stock is currently trading at CA$0.16.

    Disclosure:
    1) Patrice Fusillo compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
    2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
    3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
    4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
    5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of ProMIS, a company mentioned in this article.
    6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

    Tags:
    HEALTHCARE BIOTECHNOLOGY DRUG-MANUFACTURERS-MAJOR

    0
  • E
    Eckehardt
    PMN management needs to speed up: Acumen Pharmaceuticals/ABOS has already initiated phase1 with the antibody ACU193. Very close to PMN cpd. and one needs to understand the differentiation. The current market cap of ABOS of 580 Mio.$ indicates the upside for PMN: factor 10, if we are lucky. The technology might justify a bit more, but wo a collaboration with an established player ist will be an uphill battle. Any thoughts or different perspectives highly welcome👍
  • S
    Sue
    Very good news reported this morning by Globe Newswire, stating ProMis has announced initiation of a program to construct and test a multivalent peptide vaccine for Alzheimer’s disease. The critical first steps in vaccine development will be carried out by VIDO-InterVac, a global leader in vaccine research and development.